Movers and SHAKERS
Friday, July 10, 2020
FDA Meeting is Scheduled for October
As of April 24, 2020, Noble Capital Markets research on Neovasc is published under ticker symbols (NVCN and NVCN:CA). The price target is in USD and based on ticker symbol NVCN. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target. Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. Neovasc is developing the Tiara for the treatment of mitral valve disease. Neovasc operates its business in one segment.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
FDA meeting is scheduled. Yesterday, Neovasc announced the date for the Circulatory System Devices Panel of the Medical Devices Advisory Committee by the U.S. Food and Drug Administration (FDA). On October 27, 2020, the panel will review the premarket approval application (PMA) for Reducer.
The Reducer is for the treatment of refractory angina in the U.S. Neovasc is seeking FDA approval to commercialize the Reducer for the treatment of refractory angina in the United States. The device is currently...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.